Cortechs.ai, a global leader in AI-driven neuroimaging solutions, announced a strategic collaboration with the Alzheimer’s Network for Treatment and Diagnostics to enhance the quality of care for people living with Alzheimer’s disease. This collaboration brings together Cortechs.ai’s advanced imaging platform, NeuroQuant for ARIA, with ALZ-NET’s robust real-world data network to help inform clinical decision-making, improve care delivery and contribute to future treatment guidelines. As part of the collaboration, discounted access to NeuroQuant for ARIA will be offered to ALZ-NET sites across diverse clinical settings.
Health Technology Insights: Yellowstone High Value Network Launches with 24 Critical Access Hospitals
Cortechs.ai’s NeuroQuant for ARIA offers precise segmentation, quantification, and longitudinal tracking of both FLAIR and T2GRE/SWI lesions. This advanced functionality offers assistance with the surveillance of amyloid-related imaging abnormalities, such as ARIA-E and ARIA-H, in patients receiving anti-amyloid therapies. NeuroQuant for ARIA is validated on both 2D and 3D FLAIR sequences, ensuring compatibility with a broad range of imaging protocols. NeuroQuant for ARIA is the only clinically validated solution that detects and quantifies cerebral microbleeds and superficial siderosis on both T2GRE and SWI scans. Coupled with FLAIR lesion quantification of cerebral edema, NeuroQuant for ARIA offers a complete solution for AI-assisted monitoring of Alzheimer’s Disease patients on anti-amyloid immunotherapies.
Health Technology Insights: Philips 2025 Report Reveals Trust Gap in Healthcare AI Between Clinicians and Patients
Dr. Ana Franceschi, a nationally recognized authority in dementia imaging and molecular neuroimaging and a member of both the Cortechs.ai Medical Advisory Board and ALZ-NET’s Imaging Work Group, expressed strong support for the initiative:
“It is a privilege to serve on Cortechs.ai’s Medical Advisory Board as we embark on this important collaboration with ALZ-NET. Combining advanced neuroimaging analytics with real-world data is a critical step in optimizing safety and monitoring for Alzheimer’s patients receiving anti-amyloid therapies. This collaboration holds great promise for clinicians and patients alike.”
Sponsored by the Alzheimer’s Association and managed and operated by the American College of Radiology , ALZ-NET is a voluntary health care provider-enrolled network collecting real-world clinical and imaging data from patients evaluated for or treated with new FDA-approved Alzheimer’s therapies Through the collection of longitudinal, real-world data across a multi-site network, ALZ-NET aims to provide evidence-based critical insights into long-term safety and efficacy of Alzheimer’s therapies..
“Alzheimer’s disease is a prevalent and devastating condition that touches millions of families. Our collaboration with ALZ-NET represents a shared commitment to using data and technology to improve how we care for people with dementia,” says Kyle Frye, CEO of Cortechs.ai. “With NeuroQuant for ARIA, we’re giving clinicians the tools they need to make smarter, safer decisions, and by connecting with ALZ-NET’s powerful data network, we can collectively advance treatment practices for the entire field.”
Health Technology Insights: Eden Launches My Custom Weight Loss Kit for Personalized Metabolic Support
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
